We are live on ! Find out more
UROV

Urovant Sciences Ltd.
UROV

Delisted

UROV was delisted on the 26th of March, 2021.

Back to rankings

41 hedge funds and large institutions have $99.7M invested in Urovant Sciences Ltd. in 2020 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

84% more capital invested

Capital invested by funds: $54.2M → $99.7M (+$45.5M)

78% more funds holding

Funds holding: 23 → 41 (+18)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

Holders
41
Holders Change
+18
Holders Change %
+78.26%
% of All Funds
0.73%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
28
Increased
6
Reduced
5
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$9.3M
2
BCM
Beryl Capital Management
California
+$4.36M
3
PCM
Prelude Capital Management
New York
+$3.06M
4
GF
Gabelli Funds
New York
+$2.99M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.6M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$9.14M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$5.8M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.31M
4
PHS
Pekin Hardy Strauss
Illinois
-$4.92M
5
SB
Samsara BioCapital
California
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$50.3M +$9.3M +750,000 +32%
BCM
2
Beryl Capital Management
California
$5.67M +$4.36M +351,579 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$5.51M +$2.6M +209,939 +160%
PCM
4
Prelude Capital Management
New York
$3.99M +$3.06M +247,148 New
GF
5
Gabelli Funds
New York
$3.89M +$2.99M +241,227 New
OCM
6
Orchard Capital Management
Illinois
$3.1M +$2.38M +191,933 New
CS
7
Candriam SCA
Luxembourg
$2.71M +$2.08M +167,787 New
GCL
8
Glazer Capital LLC
New York
$2.69M +$2.07M +167,060 New
GCIA
9
Gabelli & Co Investment Advisers
New York
$2.57M +$1.97M +159,135 New
KPF
10
K2 Principal Fund
Ontario, Canada
$2.36M +$1.82M +146,556 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$1.61M +$132K +10,630 +12%
E
12
Ergoteles
New York
$1.58M +$1.21M +97,825 New
KC
13
Kellner Capital
New York
$1.45M +$1.12M +90,000 New
YCM
14
Yakira Capital Management
Connecticut
$1.29M +$992K +80,000 New
WCM
15
Wildcat Capital Management
New York
$1.05M -$365K -29,478 -31%
Bank of America
16
Bank of America
North Carolina
$1.03M +$793K +63,967 +193,839%
Northern Trust
17
Northern Trust
Illinois
$868K -$60.4K -4,871 -8%
MWNA
18
Marshall Wace North America
New York
$766K +$61.7K +4,977 +12%
SMC
19
S. Muoio & Co
New York
$765K +$587K +47,401 New
Skandinaviska Enskilda Banken (SEB)
20
Skandinaviska Enskilda Banken (SEB)
Sweden
$745K +$574K +46,299 New
Two Sigma Investments
21
Two Sigma Investments
New York
$702K +$540K +43,551 New
LA
22
LVW Advisors
New York
$636K +$7.92K +639 +2%
Marshall Wace
23
Marshall Wace
United Kingdom
$556K +$428K +34,494 New
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$474K +$364K +29,400 New
PHS
25
Pekin Hardy Strauss
Illinois
$432K -$4.92M -397,359 -94%
1
2

UROV Hedge Fund Activity: Q4 2020 in Review

41 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q4 2020, worth a combined $99.7M — up 84% from $54.2M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new UROV positions and 10 closed out — a net gain of 18 holders — while 6 added to existing stakes and 5 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $9.3M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $9.14M sold.

  • 41 institutional investors held Urovant Sciences Ltd. (UROV) as of Q4 2020, up from 23 in Q3 2020.
  • Funds reported $99.7M of Urovant Sciences Ltd. stock for Q4 2020, up 84% quarter-over-quarter.
  • 28 funds opened new Urovant Sciences Ltd. positions in Q4 2020 and 10 closed out, a net change of +18 holders.
  • The largest Urovant Sciences Ltd. buyer in Q4 2020 was Perceptive Advisors, an estimated $9.3M added.
  • The largest Urovant Sciences Ltd. seller in Q4 2020 was Baker Bros. Advisors, an estimated $9.14M sold.

Based on aggregated 13F filings for Q4 2020.